<DOC>
	<DOCNO>NCT01302106</DOCNO>
	<brief_summary>This interventional , multicenter , open label , phase II study design evaluate safety efficacy Clofarabine combination low dose Cytarabine untreated patient poor risk Myelodisplastic Syndromes .</brief_summary>
	<brief_title>Study Clofarabine Combination With Low Dose Cytarabine Treat Myelodysplastic Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>Male female patient age 55 80 year Written inform consent participate clinical trial Morphologically confirm diagnosis MDS accord WHO classification , IPSS INT2 high risk accord IPSS index ECOG performance status 02 No previous chemotherapy Serum bilirubin ≤1.5 time upper limit normal ( ULN ) ( unless elevation due primarily elevate unconjugated hyperbilirubinemia secondary Gilbert 's syndrome hemolysis , liver dysfunction ) AST ALT ≤2.5 time ULN Alkaline phosphatase ≤2.5 time ULN Serum creatinine ≤ 1 mg/dl : serum creatinine &gt; 1.0 mg/dl , estimate glomerular filtration rate ( GFR ) must &gt; 60 mL/min/1.73 m2 calculate Modification Diet Renal Disease equation Predicted GFR ( ml/min/1.73 m2 ) = 186 x ( Serum Creatinine ) 1.154 x age year 0023 x 0.742 ( patient female ) x 1.212 ( patient black ) HIV negative Have chemotherapy investigational therapy treatment MDS . Patients receive chemotherapy cancer MDS/AML enrol , provide least 6 month elapse accomplishment last course chemo . Have prior hematopoietic stem cell transplant MDS Have uncontrolled systemic fungal , bacterial , viral , infection ( define exhibit ongoing signs/symptoms related infection without improvement , despite appropriate antibiotic treatment ) . Have psychiatric disorder would interfere consent , study participation , followup . Have severe concurrent disease , history serious organ dysfunction disease involve heart Have prior treatment Clofarabine Have diagnosis another malignancy , unless patient diseasefree least 3 year follow completion curative intent therapy follow exception : . ) Patients treat nonmelanoma skin cancer , situ carcinoma , cervical intraepithelial neoplasia , regardless disease free duration , eligible study definitive treatment condition complete . b . ) Patients organconfined prostate cancer evidence recurrent progressive disease base prostatespecific antigen ( PSA ) value also eligible study hormonal therapy initiate radical prostatectomy perform . Have prior positive test Human Immunodeficiency Virus ( HIV ) , HCV , HBV .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Clofarabine</keyword>
	<keyword>Low Dose Cytarabine</keyword>
	<keyword>Poor risk MDS</keyword>
</DOC>